Clinical Study
Use of Lozenges Containing Lactobacillus brevis CD2 in Recurrent Aphthous Stomatitis: A Double-Blind Placebo-Controlled Trial
Table 1
Summary of clinical parameters before and after administration of Lactobacillus Brevis CD2 or placebo lozenges.
| | | Lactobacillus brevis CD2 () | Placebo () | Intergroup comparison |
| | | Severe () | Moderate () | Mild () | Absent () | Total Value | Severe () | Moderate () | Mild () | Absent () | Total value | |
| Burning | before | 7 | 5 | 3 | 0 | 34 | 8 | 4 | 3 | 0 | 35 | | after | 0 | 0 | 1 | 14 | 1 | 2 | 4 | 2 | 7 | 16 | |
| Spontaneous pain | before | 6 | 6 | 3 | 0 | 33 | 7 | 5 | 3 | 0 | 34 | | after | 0 | 0 | 1 | 0 | 1 | 3 | 4 | 1 | 7 | 18 | |
| Caused pain | before | 9 | 6 | 0 | 0 | 39 | 10 | 5 | 0 | 0 | 40 | | after | 0 | 0 | 1 | 14 | 1 | 5 | 2 | 1 | 7 | 20 | |
| Perilesional erythema | before | 6 | 7 | 2 | 0 | 34 | 7 | 5 | 3 | 0 | 34 | | after | 0 | 0 | 1 | 0 | 1 | 3 | 4 | 1 | 7 | 18 | |
|
|
Value assignment: 0: absent, 1: mild, 2: moderate, and 3: severe.
|